Overview

A Study Evaluating Oral Eluxadoline Administered to Pediatric Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D)

Status:
Recruiting

Trial end date:
2027-12-01

Target enrollment:

Participant gender:

Summary

This study will assess the long-term safety of oral Eluxadoline administered to pediatric participants with IBS-D who have completed study intervention in the Phase 2 study 3030-202-002 or the Phase 3 study 3030-303-002.

Phase:

Phase 3

Details

Lead Sponsor:

Allergan

Treatments:

Eluxadoline